Investor Overview

NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. We are currently focused on the development and commercialization of patented thin-film electrode technology for electrocorticography (ECoG) and stereoelectroencephalography (sEEG) recording of brain activity.

 

Company Profile

Corporate Presentation

CorporateDeckImage.JPG

Board of Directors

Paul Buckman
Chairman
Dave Rosa
President and CEO
Ed Andrle
Director

Frequently Asked Questions

When was NeuroOne incorporated?
We were originally incorporated in the state of Nevada on August 20, 2009 as Original Source Entertainment, Inc. We changed our name to NeuroOne Medical Technologies Corporation and reincorporated in Delaware before we entered into an agreement and plan of merger on July 20, 2017 to acquire NeuroOne, Inc., which was incorporated under the laws of the State of Delaware on October 7, 2016. The NeuroOne, Inc. predecessor entity, NeuroOne LLC, was formed on December 13, 2013 and operated as a limited liability company until it was merged with and into NeuroOne, Inc.

When is NeuroOne’s fiscal year end?
September 30th

Who are NeuroOne’s independent auditors?
BDO USA LLP

Can I buy stock directly from NeuroOne?
No, you will need to contact a licensed stock broker or use an online trading account

How do I get my purchased shares?
Contact Action Stock Transfer by telephone at (801) 274-1088 or by email at action@actionstocktransfer.com

What is NeurOne’s CUSIP number?
64130M100

Who can I contact for general information about NeuroOne?
Email us at contact@neurooneinc.com

Where is NeuroOne located?
7599 Anagram Drive, Eden Prairie, MN 55344

SEC Filings

SIC: 3841 - SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
State location: MN | State of Inc.: DE | Fiscal Year End: 0930

Press Releases 

NeuroOne provides updates to the market through press releases and other media coverage.